CoChat

Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial

Open access
Ford, Alexander C, Wright-Hughes, Alexandra, Alderson, Sarah L, Ow, Pei-Loo, Ridd, Matthew J, Foy, Robbie, Bianco, Gina, Bishop, Felicity L, Chaddock, Matthew, Cook, Heather, Cooper, Deborah, Fernandez, Catherine, Guthrie, Elspeth A, Hartley, Suzanne, Herbert, Amy, Howdon, Daniel, Muir, Delia P, Nath, Taposhi, Newman, Sonia, Smith, Thomas, Taylor, Christopher A, Teasdale, Emma J, Thornton, Ruth, Farrin, Amanda J, Everitt, Hazel A, Ford, Alexander C., Wright-Hughes, Alex, Alderson, Sarah L., Ow, Pei-Loo, Ridd, Matthew J., Foy, Robbie, Barratt, Maggie, Bianco, Gina, Bishop, Felicity L., Brindle, Richard, Brown, Sarah, Chaddock, Matthew, Christodoulou, Aimee, Cook, Heather, Cooper, Deborah, Day, Florence, Dowse, Aaron, Durnell, Jill, Emmerson, Jake, Fellows, Alasdair, Fernandez, Catherine, Guthrie, Elspeth A., Hartley, Suzanne, Herbert, Amy, Hindmarch, Damien, Howdon, Daniel, Malik, Aminah, Morris, Tom, Muir, Delia P., Longo, Roberta, Lopes Goncalves Graca, Sandra, Nath, Taposhi, Newman, Sonia, Parker, Catriona, Smith, Thomas, Taylor, Christopher A., Teasdale, Emma J., Thornton, Ruth, Tubeuf, Sandy, West, Amy, Williamson, Emma-Jane, Farrin, Amanda J., Everitt, Hazel A. · 2023 · The Lancet
Cited by 146

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Most patients with irritable bowel syndrome (IBS) are managed in primary care. When first-line therapies for IBS are ineffective, the UK National Institute for Health and Care Excellence guideline suggests considering low- dose tricyclic antidepressants as second-line treatment, but their effectiveness in primary care is unknown, and they are infrequently prescribed in this setting. METHODS: This randomised, double-blind, placebo-controlled trial (Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment [ATLANTIS]) was conducted at 55 general practices in England. Eligible participants were aged 18 years or older, with Rome IV IBS of any subtype, and ongoing symptoms (IBS Severity Scoring System [IBS-SSS] score ≥75 points) despite dietary changes and first-line therapies, a normal full blood count and C-reactive protein, negative coeliac serology, and no evidence of suicidal ideation. Participants were randomly assigned (1:1) to low-dose oral amitriptyline (10 mg once daily) or placebo for 6 months, with dose titration over 3 weeks (up to 30 mg once daily), according to symptoms and tolerability. Participants, their general practitioners, investigators, and the analysis team were all masked to allocation throughout the trial. The primary outcome was the IBS-SSS score at 6 months. Effectiveness analyses were according to intention-to-treat; safety analyses were on all participants who took at least one dose of the trial medication. This trial is registered with the ISRCTN Registry (ISRCTN48075063) and is closed to new participants. FINDINGS: Between Oct 18, 2019, and April 11, 2022, 463 participants (mean age 48·5 years [SD 16·1], 315 [68%] female to 148 [32%] male) were randomly allocated to receive low-dose amitriptyline (232) or placebo (231). Intention-to-treat analysis of the primary outcome showed a significant difference in favour of low-dose amitriptyline in IBS-SSS score between groups at 6 months (-27·0, 95% CI -46·9 to -7·10; p=0·0079). 46 (20%) participants discontinued low-dose amitriptyline (30 [13%] due to adverse events), and 59 (26%) discontinued placebo (20 [9%] due to adverse events) before 6 months. There were five serious adverse reactions (two in the amitriptyline group and three in the placebo group), and five serious adverse events unrelated to trial medication. INTERPRETATION: To our knowledge, this is the largest trial of a tricyclic antidepressant in IBS ever conducted. Titrated low-dose amitriptyline was superior to placebo as a second-line treatment for IBS in primary care across multiple outcomes, and was safe and well tolerated. General practitioners should offer low-dose amitriptyline to patients with IBS whose symptoms do not improve with first-line therapies, with appropriate support to guide patient-led dose titration, such as the self-titration document developed for this trial. FUNDING: National Institute for Health and Care Research Health Technology Assessment Programme (grant reference 16/162/01).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)01523-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 146

Metadata

Authors
Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Howdon, D., Muir, D. P., Nath, T., Newman, S., Smith, T., Taylor, C. A., Teasdale, E. J., Thornton, R., Farrin, A. J., Everitt, H. A., Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Barratt, M., Bianco, G., Bishop, F. L., Brindle, R., Brown, S., Chaddock, M., Christodoulou, A., Cook, H., Cooper, D., Day, F., Dowse, A., Durnell, J., Emmerson, J., Fellows, A., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Hindmarch, D., Howdon, D., Malik, A., Morris, T., Muir, D. P., Longo, R., Lopes Goncalves Graca, S., Nath, T., Newman, S., Parker, C., Smith, T., Taylor, C. A., Teasdale, E. J., Thornton, R., Tubeuf, S., West, A., Williamson, E.-J., Farrin, A. J., & Everitt, H. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-11
Volume
402
Issue
10414
Pages
1773-1785
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4387666446
Cited by
146
References
31
FWCI
34.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01523-4
The paper
Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Howdon, D., Muir, D. P., Nath, T., Newman, S., . . . Everitt, H. A. (2023). Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)01523-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.